erlotinib hydrochloride has been researched along with Thrombocythemia, Essential in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y; Hoffman, R; Ishii, T; Mascarenhas, J; Najfeld, V; Sozer, S; Wang, J; Wisch, N; Xu, M; Zhang, W; Zhao, ZJ | 1 |
1 other study(ies) available for erlotinib hydrochloride and Thrombocythemia, Essential
| Article | Year |
|---|---|
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Topics: Antigens, CD34; Cells, Cultured; Erlotinib Hydrochloride; Humans; Janus Kinase 2; Mast Cells; Mutation; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Thrombocythemia, Essential | 2009 |